EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs (Small and Medium-size companies), announced the launch of Tech 40, a label recognizing innovative European SMEs. Tech 40 puts young tech companies listed on Euronext markets – in Amsterdam, Brussels, Lisbon or Paris – under the spotlight.

Companies awarded with the Tech 40 are operating in life sciences, eco-industries or TMT (Technology-Media-Telecom). An independent group of European experts selected the best forty firms on the basis of their business, financial and stock market performances. The lucky selected companies will enjoy an inclusion in a special Tech 40 index, a roadshow programme and a membership to the Tech 40 Club.

Biotech companies, represent ¼ of the Tech 40. To prove how innovative these nominated companies are, we picked out a few names, who all made the front page recently.  

ADVERTISEMENT

Ablynx: this Belgian company is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments. They recently announce that Genzyme enters their long list of partners.

Global Bioenergies:  is developing a process to convert renewable resources into hydrocarbons through fermentation. The company just delivered in a record time their first batch of isobutene to partners like the car-maker Audi.

Innate Pharma: the company is specialized in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of natural killers and already sign major deals with Pharma companies.

Celyad (previously named Cardio3): the company is currently developing clinical stage cell therapies in cardiology and oncology, two healthcare segments with high unmet medical needs and just launched an introduction on the New York’s stock market.

What an exciting recognition for the biotech industry and congratulation to the winners of course!

Previous post

Deinove Reaches Critical Milestones and Gets Recognition in the US

Next post

Poxel is Looking towards Japan's Lucrative Diabetes Market

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.